Reactive oxygen species regulate ERBB2 and ERBB3 expression via miR‐199a/125b and DNA methylation
Open Access
- 13 November 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in EMBO Reports
- Vol. 13 (12), 1116-1122
- https://doi.org/10.1038/embor.2012.162
Abstract
Overexpression of ERBB2 or ERBB3 is associated with cancer development and poor prognosis. In this study, we show that reactive oxygen species (ROS) induce both ERBB2 and ERBB3 expression in vitro and in vivo . We also identify that miR‐199a and miR‐125b target ERBB2 and/or ERBB3 in ovarian cancer cells, and demonstrate that ROS inhibit miR‐199a and miR‐125b expression through increasing the promoter methylation of the miR‐199a and miR‐125b genes by DNA methyltransferase 1. These findings reveal that ERBB2 and ERBB3 expression is regulated by ROS via miR‐199a and miR‐125b downregulation and DNA hypermethylation.Keywords
This publication has 20 references indexed in Scilit:
- Oxidative Damage Targets Complexes Containing DNA Methyltransferases, SIRT1, and Polycomb Members to Promoter CpG IslandsCancer Cell, 2011
- miR-125b Is Methylated and Functions as a Tumor Suppressor by Regulating the ETS1 Proto-oncogene in Human Invasive Breast CancerCancer Research, 2011
- MicroRNAs as therapeutic targets in cancerTranslational Research, 2011
- Epigenetic control of the expression of a primate-specific microRNA cluster in human cancer cellsEpigenetics, 2009
- Oxidative stress, DNA methylation and carcinogenesisCancer Letters, 2008
- MicroRNA Signatures in Human Ovarian CancerCancer Research, 2007
- p38α MAP Kinase as a Sensor of Reactive Oxygen Species in TumorigenesisCancer Cell, 2007
- Effect of HER-2/neu overexpression on chemoresistance and prognosis in ovarian carcinomaJournal of Obstetrics and Gynaecology Research, 2007
- Coordinate Suppression of ERBB2 and ERBB3 by Enforced Expression of Micro-RNA miR-125a or miR-125bJournal of Biological Chemistry, 2007
- Molecular Mechanisms of Epidermal Growth Factor Receptor (EGFR) Activation and Response to Gefitinib and Other EGFR-Targeting DrugsClinical Cancer Research, 2006